Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.66 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698498 | 1.00 | KEAP1 (0.66) | KEAP1NFE2L2 | |
| SCHEMBL24473700 | 0.83 | KEAP1 (0.69) | KEAP1NFE2L2 | |
| SCHEMBL31735947 | 0.83 | KEAP1 (0.69) | KEAP1NFE2L2 | |
| SCHEMBL29698419 | 0.82 | KEAP1 (0.67) | KEAP1NFE2L2 | |
| SCHEMBL29908080 | 0.81 | KEAP1 (0.78) | KEAP1NFE2L2 | |
| SCHEMBL29698477 | 0.81 | KEAP1 (0.78) | KEAP1NFE2L2 | |
| SCHEMBL25046238 | 0.81 | KEAP1 (0.78) | KEAP1NFE2L2 | |
| SCHEMBL29358083 | 0.80 | KEAP1 (1.00) | KEAP1NFE2L2 | |
| SCHEMBL29699866 | 0.79 | KEAP1 (0.86) | KEAP1NFE2L2 | |
| SCHEMBL29378881 | 0.78 | KEAP1 (1.00) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071491-A1 | MICROORGANISM HAVING MYCOSPORINE-LIKE AMINO ACID PRODUCING ABILITY, AND METHOD FOR PRODUCING MYCOSPORINE-LIKE AMINO ACIDS USING SAME | 큐티스바이오 주식회사 | 2024-04-04 | — | — | WO | claimed |
| CN-112292452-B | Microorganism producing mycosporine-like amino acid and method for producing mycosporine-like amino acid using the same | CJ第一制糖株式会社 | 2024-02-06 | — | — | CN | claimed |
| CN-111527211-B | Microorganism producing mycosporine-like amino acid and method for producing mycosporine-like amino acid using the same | CJ第一制糖株式会社 | 2023-12-01 | — | — | CN | claimed |
| EP-3670661-B1 | MICROORGANISM PRODUCING MYCOSPORINE-LIKE AMINO ACID AND MICOSPORINE-LIKE AMINO ACID PRODUCTION METHOD USING SAME | CJ CHEILJEDANG CORP (KR) | 2023-11-01 | — | — | EP | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20230064780-A1 | MYCOSPORINE-LIKE AMINO ACID-PRODUCING MICROORGANISM AND METHOD FOR PRODUCTION OF MYCOSPORINE-LIKE AMINO ACIDS BY USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2023-03-02 | — | — | US | claimed |
| EP-3754024-B1 | A MICROORGANISM PRODUCING A MYCOSPORINE-LIKE AMINO ACID AND A METHOD FOR PRODUCING A MYCOSPORINE-LIKE AMINO ACID USING THE SAME | CJ CHEILJEDANG CORP (KR) | 2022-07-27 | — | — | EP | claimed |
| US-20260043057-A1 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4650435-A1 | MYCOSPORINE-LIKE AMINO ACID-CONTAINING FUNGAL BODY, AND METHOD FOR PRODUCING EXTRACT THEREOF | Nissui Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4650433-A1 | MYCOSPORINE-GLUTAMINE-CONTAINING EXTRACT | Nissui Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| EP-4650454-A1 | METHOD FOR EXTRACTING MYCOSPORINE-LIKE AMINO ACIDS | Nissui Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| US-12378562-B2 | Gadusol derivative production in bacteria | OREGON STATE UNIVERSITY (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025088920-A1 | MYCOSPORINE-CONTAINING COMPOSITION | 株式会社ニッスイ | 2025-05-01 | — | — | WO | disclosed |
| EP-3670661-B1 | MICROORGANISM PRODUCING MYCOSPORINE-LIKE AMINO ACID AND MICOSPORINE-LIKE AMINO ACID PRODUCTION METHOD USING SAME | CJ CHEILJEDANG CORP (KR) | 2023-11-01 | — | — | EP | disclosed |
| US-11739337-B2 | Gadusol derivative production in bacteria | OREGON STATE UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230064780-A1 | MYCOSPORINE-LIKE AMINO ACID-PRODUCING MICROORGANISM AND METHOD FOR PRODUCTION OF MYCOSPORINE-LIKE AMINO ACIDS BY USING SAME | CJ CHEILJEDANG CORPORATION (KR) | 2023-03-02 | — | — | US | disclosed |
| WO-2022217117-A1 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-2022203228-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES CAUSED BY ULTRAFINE PARTICULATE MATTER COMPRISING PORPHYRA TENERA EXTRACT AS ACTIVE INGREDIENT | 경상국립대학교산학협력단 | 2022-09-29 | — | — | WO | disclosed |
| EP-3754024-B1 | A MICROORGANISM PRODUCING A MYCOSPORINE-LIKE AMINO ACID AND A METHOD FOR PRODUCING A MYCOSPORINE-LIKE AMINO ACID USING THE SAME | CJ CHEILJEDANG CORP (KR) | 2022-07-27 | — | — | EP | disclosed |
| US-11384370-B2 | Microorganism for producing a mycosporine-like amino acid and method for producing a mycosporine-like amino acid using the same | CJ CHEILJEDANG CORPORATION (KR) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260043057-A1 | ENZYMATIC SYNTHESIS OF MYCOSPORINE-LIKE AMINO ACIDS | ALAD, AHCY, DAO | KEAP1 590/4885NFE2L2 1089/4885 |
| US-11739337-B2 | Gadusol derivative production in bacteria | MLYCD, UROD, ODC1 | KEAP1 2024/4885NFE2L2 2893/4885 |
| US-12378562-B2 | Gadusol derivative production in bacteria | MLYCD, UROD, ODC1 | KEAP1 2024/4885NFE2L2 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.